AgPlus Diagnostics Ltd today announced that they have signed a contract with AstraZeneca to develop a prototype diagnostic. The agreement will cover AgPlus Diagnostics developing a diagnostic assay for potential use as part of a personalised approach to treating respiratory disease.
Keith Page, CEO of AgPlus Diagnostics, said “This is a great new collaboration for AgPlus and recognises the strength of the AgPlus technology and the strength of healthcare development in the UK. AgPlus sees itself as a leading innovator in new technology for diagnostics and is proud to be associated with AstraZeneca, a global leader in biopharmaceuticals.”
AgPlus’ platform technology combines novel electrochemistry and metallic nanoparticles signaling with diagnostic immunoassays to provide high sensitivity and fully quantitative analyte detection. It is anticipated that the AgPlus ADVANTAGETM handheld portable reader and single use test cartridge may be utilised in primary care settings to assist physicians with treatment decisions.
If successful, the prototype device could potentially be developed into a commercial product to accompany AstraZeneca’s respiratory product portfolio.
Ruth March, VP and Head of AstraZeneca Personalised Healthcare & Biomarkers, said “Through this partnership, we hope to make available a quick and innovative point-of-care diagnostic to respiratory patients through their physicians. If successful, this diagnostic could be used to measure several biomarkers, which would support our goal of matching patients with the right treatment using their individual biomarker profiles.”
Full text of Press Release can be downloaded here: AgPlus Diagnostics to Develop Point of Care Test for AstraZeneca 21st Sept 2016